Physician profile
Roy Dewayne Book
NPI 1245437631
$4,126.81
in general payments reported to CMS, 2019-2025
25 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what 86% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $77.85 · 2021: $41.23 · 2022: $34.03 · 2023: $475 · 2024: $1,540 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,474 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,473.54 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.25 | 2022-2025 | Vraylar |
| Allergan, INC. | $455.58 | 2019-2020 | |
| Alkermes, INC. | $425.40 | 2019-2025 | Aristada, Vivitrol, Lybalvi |
| Lundbeck LLC | $420.06 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $415.10 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $275.34 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $233.36 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $223.87 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $173.38 | 2020-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $133.73 | 2024-2025 | Spravato |
| Bausch Health US, LLC | $127.97 | 2023-2025 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $89.55 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $84.67 | 2024 | |
| Tris Pharma INC | $83.24 | 2024-2025 | Dyanavel Xr |
| Indivior INC. | $81.29 | 2022-2025 | Sublocade |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $78.37 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $68.57 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $64.72 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Orexo US, INC. | $57.81 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $48.50 | 2025 | Hetlioz, Fanapt |
| Noven Therapeutics, LLC | $43.72 | 2023-2024 | Xelstrym |
| Biogen, INC. | $23.87 | 2025 | Zurzuvae |
| Braeburn INC. | $21.94 | 2025 | Brixadi |
| Tms Neurohealth Centers INC. | $20.53 | 2025 | Tms Neurohealth Centers INC. |
| Neos Therapeutics, Lp | $13.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Book listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.